Cardiac-Oncology Toxicity in Breast Cancer
Research type
Research Study
Full title
Cardiac Oncology Toxicity in Breast Cancer (ESC-COT) EACVI-HFA Registry
IRAS ID
193404
Contact name
Stam Kapatanakis
Contact email
Sponsor organisation
European Society of Cardiology
Duration of Study in the UK
2 years, 4 months, 31 days
Research summary
Cancer and cardiovascular diseases are the leading cause of death in the Western World. Newer cancer therapies have improved the survival of cancer patients but in some cases side effects from cancer treatments and cause long term cardiovascular diseases and in tern can be the main determinant of quality of life and in some cases the cause of premature mortality. Cancer drug treatments can affect the heart function and studies have demonstrated that up to 27% patients may be affected. Recent studies have raised the debate on how damaging these drugs are in a real world setting. This registry aims to define risk factors for heart dysfunction during/following treatment, the incidence of both symptomatic and non-symptomatic drug related cardio-toxicity, the impact on treatment regimes and the type of cardioprotective drugs and treatments used. This observational study will recruit patients who are undergoing assessment of their heart function whilst undergoing chemotherapy for breast cancer. This is purely an observational study with no additional tests or procedures performed. Patients will have their routine care observed for one year.
REC name
London - Central Research Ethics Committee
REC reference
16/LO/1326
Date of REC Opinion
3 Aug 2016
REC opinion
Further Information Favourable Opinion